Molecular Cancer Therapeutics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Published online first on April 29, 2008
[Molecular Cancer Therapeutics, 10.1158/1535-7163.MCT-07-2220]
This Article
Right arrow Full Text (Online First [PDF])
Right arrow All Versions of this Article:
1535-7163.MCT-07-2220v1
7/5/1258    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raina, K.
Right arrow Articles by Agarwal, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raina, K.
Right arrow Articles by Agarwal, C.

Research Articles: Therapeutics, Targets, and Development

Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice

Komal Raina 1, Subapriya Rajamanickam , Gagan Deep , Meenakshi Singh , Rajesh Agarwal , Chapla Agarwal *

1 1Department of Pharmaceutical Sciences, School of Pharmacy, 2Department of Pathology, and 3University of Colorado Cancer Center, University of Colorado-Denver, Denver, Colorado

* To whom correspondence should be addressed. E-mail: Chapla.Agarwal{at}uchsc.edu.


   Abstract

Our recent studies have identified gallic acid as one of the major constituents of grape seed extract showing strong in vitro anticancer efficacy against human prostate cancer cells. Herein, for the first time, we established the in vivo chemopreventive efficacy of gallic acid against prostate cancer by evaluating its activity against prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate (TRAMP) model. At 4 weeks of age, male TRAMP mice were fed with drinking water supplemented with 0.3% and 1% (w/v) gallic acid until 24 weeks of age. Positive control group was fed with regular drinking water for the same period. Our results showed that gallic acid–fed groups had a higher incidence of differentiated lower-grade prostatic tumors at the expense of strong decrease (~60%; P < 0.01) in poorly differentiated tumors. Immunohistochemical analysis of prostate tissue showed a decrease in proliferative index by 36% to 41% (P < 0.05) in 0.3% to 1% gallic acid–fed groups, with an increase in the apoptotic cells by 3-fold (P < 0.05). Further, both doses of gallic acid completely diminished the expression of Cdc2 in the prostatic tissue together with strong decrease in the expression of Cdk2, Cdk4, and Cdk6. The protein levels of cyclin B1 and E were also decreased by gallic acid feeding. Together, for the first time, we identified that oral gallic acid feeding inhibits prostate cancer growth and progression to advanced-stage adenocarcinoma in TRAMP mice via a strong suppression of cell cycle progression and cell proliferation and an increase in apoptosis. [Mol Cancer Ther 2008;7(5):OF1–10]

Key Words: chemoprevention, TRAMP, prostate cancer progression, cell cycle regulation, gallic acid, grape seed extract







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.